Peginterferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection [3] (multiple letters)

New England Journal of Medicine

Volumn 353, Issue 11, 2005, Pages 1182-1183

  Borg, Brian B ^a   Hoofnagle, Jay H ^a   Henry, Michael J ^b   Mangia, Alessandra ^c   Andriulli, Angelo ^c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2B INTERFERON; ANTIVIRUS AGENT; PEGINTERFERON ALFA-2B; VIRUS RNA;

BODY MASS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DEMOGRAPHY; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEPATITIS C; HUMAN; LETTER; PRIORITY JOURNAL; RACE; SAFETY; SEX; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; GENETICS; HEPATITIS C VIRUS; MALE; NOTE; EUROPE; UNITED STATES;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; RIBAVIRIN; RNA, VIRAL; BODY MASS INDEX; EUROPE; UNITED STATES;

EID: 24944519999     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMc052008     Document Type: Letter

References (0)